Ipamorelin
Also indexed as selective growth hormone secretagogue · GHRP-like secretagogue
Ipamorelin is a pentapeptide described in 1998 as a selective growth-hormone secretagogue. Its foundational work is pharmacology in cells and animals; that is the useful scope for this page.
Last reviewed 2026-09-07 · education only
What it is doing in the literature
It acts through a GHRP-like secretagogue receptor pathway to stimulate growth-hormone release in experimental systems. The selectivity claim belongs to the cited experiments and should not be stretched into treatment advice.
History & development
- 1998
A paper titled “Ipamorelin, the first selective growth hormone secretagogue” described its discovery from a chemistry program and its preclinical pharmacology.
Approved brands & pathway
Ipamorelin is presented for research-name and evidence literacy. A research name does not authenticate a product or establish a human-use pathway.
Evidence entries
Topic: Endocrine · growth-hormone research · Category: Endocrine
Ipamorelin
What the source supports
Preclinical growth-hormone secretagogue pharmacology
The foundational pharmacology paper describes ipamorelin as a selective growth-hormone secretagogue in experimental systems; it does not establish evidence for a CJC-1295/Ipamorelin combination.
Limit: Preclinical pharmacology does not establish efficacy, safety, dosing or quality for an Ipamorelin or CJC-1295 marketplace material.
Source: Ipamorelin foundational pharmacology · PubMed Read source ↗
Grade mix in this atlas
Grades describe the cited record for a narrow question. They do not score a marketplace material or make a health decision.
Naming curiosities & useful distinctions
- The name is associated with a secretagogue class, not an approved brand.
- Ipamorelin is often paired with CJC-1295 in online language, while the cited evidence entries do not establish a combined product or clinical pathway.
Selectivity is a study result
The original paper tested receptor and hormone-response questions in experimental systems. “Selective” is a useful paper descriptor, not a guarantee about an unverified product.
Who is named in the record
Research author
Kirsten Raun and colleagues
The foundational paper describes ipamorelin's identification and pharmacology; it does not establish an approved product.